---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting. Topics: Evaluation for long-term prophylaxis: guideline recommendation, First-line long-term prophylaxis agents: WAO guideline, Pediatric guideline: criteria and first-line agents by age, Criteria for starting long-term prophylaxis: health technology assessment, and 8 further topics. 13 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary

A 2026 guideline (Vázquez et al.) recommends that all patients with HAE be evaluated for long-term prophylaxis at every visit through shared decision-making, and lists subcutaneous plasma-derived C1 inhibitor, lanadelumab, berotralstat, garadacimab, and donidalorsen as first-line options. The 2026 pediatric guideline recommends lanadelumab or plasma-derived C1 inhibitor for children aged between 6 and 12 years, and adds berotralstat and garadacimab for adolescents aged 12 years or older. Both guidelines recommend supplying on-demand treatment for at least 2 attacks during prophylaxis, and the Vázquez et al. guideline recommends management by physicians with expertise in HAE supported by a referral center.

Onvuzosiran is an investigational small interfering RNA and appears in no guideline list of first-line agents. The sponsor is developing it for prevention of HAE attacks as a subcutaneous injection every 3 or 6 months, both intervals being studied in the phase 3 STOP-HAE trial, and a 2025 review describes it as in development for long-term prophylaxis in HAE type I/II. STOP-HAE requires participants to complete any washout of long-term prophylaxis before screening and to have access to an acute therapy, so its results will describe onvuzosiran as the only long-term prophylactic agent, compared with placebo, with on-demand treatment available. The sources do not state whether onvuzosiran would be self-administered or given by a health care professional; the guideline states that self-administration and home therapy are available for current agents including lanadelumab, garadacimab, and donidalorsen.

Other prophylactic agents in late-stage development include navenibart, a plasma kallikrein inhibitor dosed subcutaneously every 3 or 6 months in a phase 3 trial with top-line results expected in Q3 2027; deucrictibant XR, with an NDA submission planned for the first half of 2027; lonvoguran ziclumeran, intended as a single-dose therapy, with a PDUFA target action date of March 10, 2027; and BW-20805, a second prekallikrein-directed siRNA dosed every 12 or 24 weeks in a study of 25 participants with HAE.

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/); [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/); [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/); [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm); [ADARx Pharmaceuticals](https://stophae.com/); [BioCryst Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm); [Pharvaris (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm); [Intellia Therapeutics (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license); [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

<a id="topic-2.2.2.2-2"></a>

### Evaluation for long-term prophylaxis: guideline recommendation

> “We recommend that all patients with HAE are evaluated for LTP at every visit, with a shared decision-making approach.”
> “Successful LTP implies full disease control with minimal treatment burden and requires patient adherence, so that a shared decision-making approach is essential.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-3"></a>

### First-line long-term prophylaxis agents: WAO guideline

> “We recommend SC pdC1-INH, lanadelumab, berotralstat, garadacimab, or donidalorsen as first-line options for LTP.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-4"></a>

### Pediatric guideline: criteria and first-line agents by age

> “We recommend evaluating frequency and location of angioedema attacks, burden of disease, quality of life, patients' and caregivers' preferences, and availability of medications when considering long‐term prophylaxis.”
> “In children with hereditary angioedema due to C1 inhibitor deficiency aged between 6 and 12 years, we recommend the use of lanadelumab or plasma‐derived C1 inhibitor as first‐line long‐term prophylaxis.”
> “In adolescents with hereditary angioedema due to C1 inhibitor deficiency aged 12 years or older, we recommend the use of any of the following treatments: berotralstat or garadacimab or lanadelumab or plasma‐derived C1 inhibitor, as first‐line long‐term prophylaxis.”

Source: [Farkas et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13466006/)

<a id="topic-2.2.2.2-5"></a>

### Criteria for starting long-term prophylaxis: health technology assessment

> “There are currently no consensus criteria on when to consider starting long-term prophylaxis for patients with HAE 1/2.”

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf)

<a id="topic-2.2.2.2-6"></a>

### Onvuzosiran in guideline and review discussion of investigational agents

> “ADX-324, a small-interfering RNA, is currently being investigated for HAE and looks promising to be an every 6 month subcutaneously injected medication.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

> “ADX-324 is a short interfering RNA (siRNA) in development for long-term prophylaxis in HAE type I/II.”

Source: [Uminski et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12618362/)

<a id="topic-2.2.2.2-7"></a>

### Sponsor-stated intended use and dosing intervals

> “We are developing onvuzosiran as a Q6M and Q3M SC treatment for the prevention of HAE attacks.”
> “Onvuzosiran is delivered via SC administration, with target dosing intervals of Q6M and Q3M being studied in our ongoing, Phase 3 STOP-HAE clinical trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “for onvuzosiran, an investigational small interfering RNA (siRNA) therapeutic candidate, for prophylaxis to prevent attacks of hereditary angioedema (HAE).”

Source: [ADARx Pharmaceuticals Fast Track designation announcement (2026)](https://www.adarx.com/adarx-pharmaceuticals-receives-fda-fast-track-designation-for-onvuzosiran-for-the-treatment-of-hae/)

<a id="topic-2.2.2.2-8"></a>

### Sponsor-stated rationale relative to current prophylaxis

> “Therefore, prophylaxis is the preferred approach for most patients.”
> “Taken together, there is remaining unmet medical need in HAE for a potent and long duration of action preventative therapy to provide patients with maximal attack suppression with lower burden of treatment, improved treatment compliance and enhanced quality of life.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

<a id="topic-2.2.2.2-9"></a>

### Phase 3 trial population: discontinuation of prior prophylaxis

> “It is administered every 3 or 6 months, potentially helping to make managing HAE simpler by requiring fewer doses compared to current treatments.”
> “Be willing to stop any long-term, preventative medication used to prevent attacks”
> “Have access to at least one acute therapy that has worked for you before”

Source: [ADARx Pharmaceuticals](https://stophae.com/)

<a id="topic-2.2.2.2-10"></a>

### Pipeline: navenibart, long-acting plasma kallikrein inhibitor

> “The company is studying navenibart, an investigational, long-acting plasma kallikrein inhibitor, in ALPHA-ORBIT, the ongoing and fully enrolled pivotal study in hereditary angioedema with every three-month and every six-month subcutaneous dosing, and ORBIT-EXPANSE, the long-term extension study.”
> “The program remains on track to report top-line results at six- and twelve-month endpoints in Q3 2027.”

Source: [BioCryst Pharmaceuticals (2026)](https://www.sec.gov/Archives/edgar/data/882796/000117184326007097/exh_991.htm)

> “Navenibart, a human monoclonal antibody targeting plasma kallikrein and engineered with Fc region modifications that extend its half-life to approximately 100 days, has advanced into phase 3 clinical trials.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-11"></a>

### Pipeline: deucrictibant, oral bradykinin B2 receptor antagonist

> “Treatment with deucrictibant XR in participants with all types of HAE reduced the mean monthly attack rate by 83% (p<0.0001)”
> “Preparation of NDA dossier of deucrictibant XR for prophylaxis of AE-BK attacks ongoing; timeline remains on-track for submission in 1H2027”

Source: [Pharvaris (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-2.2.2.2-12"></a>

### Pipeline: lonvoguran ziclumeran, in vivo gene editing

> “today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA Priority Review with a PDUFA target action date of March 10, 2027.”

Source: [Intellia Therapeutics (2026)](https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-announces-fda-acceptance-biologics-license)

> “The goal of this therapy is to provide lifelong control of HAE attacks with just a single dose.”

Source: [Vázquez et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13184495/)

<a id="topic-2.2.2.2-13"></a>

### Pipeline: BW-20805, prekallikrein-directed siRNA

> “BW-20805 is an investigational siRNA therapeutic designed to silence plasma prekallikrein (PKK) messenger RNA, targeting a clinically validated pathway in HAE.”
> “As of the June 2026 data cut-off, 25 participants were randomized and dosed across three treatment groups: BW-20805: 600 mg every 24 weeks (Q24W), 300 mg Q24W, and 300 mg every 12 weeks (Q12W).”
> “Mean time-normalized monthly attack rates decreased by 83% in the 600 mg Q24W group, 96% in the 300 mg Q24W group, and 93% in the 300 mg Q12W group”

Source: [Argo Biopharma (2026)](https://www.prnewswire.com/news-releases/argo-biopharma-to-present-positive-phase-ii-updated-results-of-sirna-therapeutic-bw-20805-for-hae-at-bradykinin-symposium-2026-302869556.html)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
